10 [105] N. Begum and L. Ragolia, “Eﬀect of tumor necrosis factor- α on insulin action in cultured rat skeletal muscle cells,” Endocrinology, vol. 137, no. 6, pp. 2441–2446, 1996. [106] T. Suganami, J. Nishida, and Y. Ogawa, “A paracrine loop between adipocytes and macrophages aggravates inﬂamma- tory changes: role of free fatty acids and tumor necrosis factor α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2062–2068, 2005. [107] G. S. Hotamisligil, “Inﬂammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006. [108] M. Tesauro, F. Schinzari, V. Rovella et al., “TNF-alpha antag- onism improves insulin-stimulated vasodilation in metabolic syndrome,” Diabetes Care, vol. 31, no. 7, pp. 1439–1441, 2008. [109] R. E. Gimeno and L. D. Klaman, “Adipose tissue as an active endocrine organ: recent advances,” Current Opinion in Pharmacology, vol. 5, no. 2, pp. 122–128, 2005. [110] M. Feuerer, L. Herrero, D. Cipolletta et al., “Lean, but not obese, fat is enriched for a unique population of regulatory T cells that aﬀect metabolic parameters,” Nature Medicine, vol. 15, no. 8, pp. 930–939, 2009. [111] G. Iacobellis, C. R. di Gioia, D. Cotesta et al., “Epicardial adi- pose tissue adiponectin expression is related to intracoronary adiponectin levels,” Hormone and Metabolic Research, vol. 41, no. 3, pp. 227–231, 2009. [112] G. Barbaro and G. Iacobellis, “Metabolic syndrome asso- ciated with HIV and highly active antiretroviral therapy,” Current Diabetes Reports, vol. 9, no. 1, pp. 37–42, 2009. [113] G. Iacobellis, D. Pistilli, M. Gucciardo et al., “Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease,” Cytokine, vol. 29, no. 6, pp. 251–255, 2005. [114] T. Mazurek, L. Zhang, A. Zalewski et al., “Human epicardial adipose tissue is a source of inﬂammatory mediators,” Circulation, vol. 108, no. 20, pp. 2460–2466, 2003. [115] A. R. Baker, N. F. da Silva, D. W. Quinn et al., “Human epicardial adipose tissue expresses a pathogenic proﬁle of adipocytokines in patients with cardiovascular disease,” Cardiovascular Diabetology, vol. 5, article 1, 2006. [116] G. N. Chaldakov, M. Fiore, I. S. Stankulov et al., “Neu- rotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovas- cular disease?” Progress in Brain Research, vol. 146, pp. 279– 289, 2004. [117] J. Kremen, M. Dolinkova, J. Krajickova et al., “Increased subcutaneous and epicardial adipose tissue production of proinﬂammatory cytokines in cardiac surgery patients: pos- sible role in postoperative insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4620–4627, 2006. [118] Y. J. Gao, Z. H. Zeng, K. Teoh et al., “Perivascular adipose tissue modulates vascular function in the human internal thoracic artery,” Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 4, pp. 1130–1136, 2005. [119] A. S. Greenstein, K. Khavandi, S. B. Withers et al., “Local inﬂammation and hypoxia abolish the protective anticon- tractile properties of perivascular fat in obese patients,” Circulation, vol. 119, no. 12, pp. 1661–1670, 2009. [120] R. Djaberi, J. D. Schuijf, J. M. van Werkhoven, G. Nucifora, J. W. Jukema, and J. J. Bax, “Relation of epicardial adipose tissue to coronary atherosclerosis,” American Journal of Cardiology, vol. 102, no. 12, pp. 1602–1607, 2008. Cardiology Research and Practice [121] N. Hosogai, A. Fukuhara, K. Oshima et al., “Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation,” Diabetes, vol. 56, no. 4, pp. 901–911, 2007. [122] N. Kambham, G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D’Agati, “Obesity-related glomerulopathy: an emerging epidemic,” Kidney International, vol. 59, no. 4, pp. 1498– 1509, 2001. [123] O. Lamacchia, V. Nicastro, D. Camarchio et al., “Para and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients,” Nephrology, Dialysis, Transplantation. In press. [124] D. K. Papafragkaki and G. Tolis, “Obesity and renal disease: a possible role of leptin,” Hormones, vol. 4, no. 2, pp. 90–95, 2005. [125] J. E. Hall, D. W. Jones, J. J. Kuo, A. da Silva, L. S. Tallam, and J. Liu, “Impact of the obesity epidemic on hypertension and renal disease,” Current Hypertension Reports, vol. 5, no. 5, pp. 386–392, 2003. [126] E. Morales, M. A. Valero, M. Leo´ n, E. Herna´ndez, and M. Praga, “Beneﬁcial eﬀects of weight loss in overweight patients with chronic proteinuric nephropathies,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 319–327, 2003. [127] M. Praga, E. Hernandez, J. C. Herrero et al., “Inﬂuence of obesity on the appearance of proteinuria and renal insuf- ﬁciency after unilateral nephrectomy,” Kidney International, vol. 58, no. 5, pp. 2111–2118, 2000. [128] C. Rask-Madsen, H. Dom´ınguez, N. Ihlemann, T. Hermann, L. Køber, and C. Torp-Pedersen, “Tumor necrosis factor-α inhibits insulin’s stimulating eﬀect on glucose uptake and endothelium-dependent vasodilation in humans,” Circula- tion, vol. 108, no. 15, pp. 1815–1821, 2003. [129] A. Picchi, X. Gao, S. Belmadani et al., “Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome,” Circulation Research, vol. 99, no. 1, pp. 69–77, 2006. [130] A. E. Caballero, “Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease,” Obesity Research, vol. 11, no. 11, pp. 1278–1289, 2003. [131] S. V. De Kreutzenberg, M. Puato, E. Kiwanuka et al., “Elevated non-esteriﬁed fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels,” Atherosclerosis, vol. 169, no. 1, pp. 147–153, 2003. [132] M. E. Griﬃn, M. J. Marcucci, G. W. Cline et al., “Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade,” Diabetes, vol. 48, no. 6, pp. 1270–1274, 2000. [133] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 3015–3025, 2006. [134] N. Houstis, E. D. Rosen, and E. S. Lander, “Reactive oxygen species have a causal role in multiple forms of insulin resistance,” Nature, vol. 440, no. 7086, pp. 944–948, 2006. [135] G. Zeng and M. J. Quon, “Insulin-stimulated production of nitric oxide is inhibited by Wortmannin: direct measurement in vascular endothelial cells,” Journal of Clinical Investigation, vol. 98, no. 4, pp. 894–898, 1996. [136] M. A. Vincent, L. H. Clerk, J. R. Lindner et al., “Microvascular recruitment is an early insulin eﬀect that regulates skeletal muscle glucose uptake in vivo,” Diabetes, vol. 53, no. 6, pp. 1418–1423, 2004.